Gebrechliches Profil, das Standard- FL-Kombinationsimmunchemo (BR / R-CHOP / G-B / R...
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | RF-FL-FRAILTY-AGE |
|---|---|
| Art | Warnhinweis |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Erkrankungen | DIS-FL |
| Quellen | SRC-ESMO-FL-2024 SRC-NCCN-BCELL-2025 |
Ursprung der Roten Flagge
| Begriffsbestimmung | Frailty profile precluding standard FL combination immunochemo (BR / R-CHOP / G-B / R-Len): ECOG ≥3, OR (age ≥80 with any moderate comorbidity), OR composite frailty (age ≥75 + Charlson ≥3 + albumin <3.5). Triggers de-escalation to rituximab monotherapy or rituximab + chlorambucil (well-tolerated, palliative-curative balance). |
|---|---|
| Klinische Richtung | Eskalation |
| Kategorie | Gebrechlichkeit |
Logik auslösen
{
"any_of": [
{
"comparator": ">=",
"finding": "ecog",
"threshold": 3
},
{
"all_of": [
{
"comparator": ">=",
"finding": "age",
"threshold": 80
},
{
"comparator": ">=",
"finding": "comorbidity_grade2_count",
"threshold": 1
}
]
},
{
"all_of": [
{
"comparator": ">=",
"finding": "age",
"threshold": 75
},
{
"comparator": ">=",
"finding": "charlson_score",
"threshold": 3
},
{
"comparator": "<",
"finding": "albumin_g_dl",
"threshold": 3.5
}
]
}
],
"type": "composite_score"
}
Anmerkungen
FL is indolent and frequently watch-and-wait appropriate. When treatment is required (per GELF criteria), rituximab monotherapy weekly x4 then maintenance — well-tolerated, response durable in low-burden disease, and can be repeated at progression. Rituximab + chlorambucil oral schedule (StiL NHL2) reasonable for mid-frailty. Avoid bendamustine in elderly with active infection / prior PJP / hypogamma — opportunistic infection risk substantial. Lenalidomide in frail elderly causes cytopenias / fatigue — start reduced-dose (10 mg) and titrate.
Verwendet von
Keine Rückverweise im YAML-Korpus gefunden.